ZYME · Healthcare
Zymeworks Inc
16/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
21
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$1.8B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ZYMEWORKS INC
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera…
Who's behind the signal
Every informed buyer we can see on ZYME, across all three feeds.
Hedge funds · 4
Citadel Advisors
Increased +350%
Tudor Investment (Paul Tudor Jones)
Increased +22%
D.E. Shaw & Co
Increased +5%
AQR Capital Management
Unchanged
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ZYMEWORKS INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
0
New positions
3
Increasing
0
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+350%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+22%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+5%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
—
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ZYMEWORKS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ZYMEWORKS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime